| pubmed-article:16343292 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16343292 | lifeskim:mentions | umls-concept:C1280551 | lld:lifeskim |
| pubmed-article:16343292 | lifeskim:mentions | umls-concept:C0232804 | lld:lifeskim |
| pubmed-article:16343292 | lifeskim:mentions | umls-concept:C0003015 | lld:lifeskim |
| pubmed-article:16343292 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:16343292 | lifeskim:mentions | umls-concept:C0145162 | lld:lifeskim |
| pubmed-article:16343292 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:16343292 | pubmed:dateCreated | 2005-12-13 | lld:pubmed |
| pubmed-article:16343292 | pubmed:abstractText | The objective of this study was to investigate renal function in clinically normal dogs receiving tepoxalin, a nonsteroidal inflammatory drug, either in association with or without an angiotensin-converting enzyme inhibitor (ACEI). Ten adult female Beagle dogs were used in the three phases of the study. The dogs were administered the drugs once daily for 7 days (experiment 1: placebo/tepoxalin/tepoxalin and benazepril; experiment 2: enalapril/tepoxalin and enalapril) or for 28 days (experiment 3: tepoxalin and benazepril together). Renal function was assessed by measurement of glomerular filtration rate (GFR) by renal scintigraphy [(renal uptake of 99mTc-diethylenetriaminepentacetic acid (DTPA)] and plasma clearance of 99mTc-DTPA. Compared with the placebo group, renal uptake and plasma clearance of 99mTc-DTPA were not significantly modified after a 7-day period of treatment with tepoxalin or enalapril alone, tepoxalin and benazepril or tepoxalin and enalapril together. No significant change was obtained in GFR after a 28-day period of dosing with tepoxalin and benazepril together. Therefore, it was concluded that tepoxalin did not alter renal function in healthy Beagle dogs receiving ACEI. | lld:pubmed |
| pubmed-article:16343292 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16343292 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16343292 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16343292 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16343292 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16343292 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16343292 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16343292 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16343292 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16343292 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16343292 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16343292 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16343292 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16343292 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:16343292 | pubmed:issn | 0140-7783 | lld:pubmed |
| pubmed-article:16343292 | pubmed:author | pubmed-author:GautierFF | lld:pubmed |
| pubmed-article:16343292 | pubmed:author | pubmed-author:GognyMM | lld:pubmed |
| pubmed-article:16343292 | pubmed:author | pubmed-author:MadecSS | lld:pubmed |
| pubmed-article:16343292 | pubmed:author | pubmed-author:DebailleulMM | lld:pubmed |
| pubmed-article:16343292 | pubmed:author | pubmed-author:MarescauxLL | lld:pubmed |
| pubmed-article:16343292 | pubmed:author | pubmed-author:FusellierMM | lld:pubmed |
| pubmed-article:16343292 | pubmed:author | pubmed-author:DesfontisJ-CJ... | lld:pubmed |
| pubmed-article:16343292 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16343292 | pubmed:volume | 28 | lld:pubmed |
| pubmed-article:16343292 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16343292 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16343292 | pubmed:pagination | 581-6 | lld:pubmed |
| pubmed-article:16343292 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:16343292 | pubmed:meshHeading | pubmed-meshheading:16343292... | lld:pubmed |
| pubmed-article:16343292 | pubmed:meshHeading | pubmed-meshheading:16343292... | lld:pubmed |
| pubmed-article:16343292 | pubmed:meshHeading | pubmed-meshheading:16343292... | lld:pubmed |
| pubmed-article:16343292 | pubmed:meshHeading | pubmed-meshheading:16343292... | lld:pubmed |
| pubmed-article:16343292 | pubmed:meshHeading | pubmed-meshheading:16343292... | lld:pubmed |
| pubmed-article:16343292 | pubmed:meshHeading | pubmed-meshheading:16343292... | lld:pubmed |
| pubmed-article:16343292 | pubmed:meshHeading | pubmed-meshheading:16343292... | lld:pubmed |
| pubmed-article:16343292 | pubmed:meshHeading | pubmed-meshheading:16343292... | lld:pubmed |
| pubmed-article:16343292 | pubmed:meshHeading | pubmed-meshheading:16343292... | lld:pubmed |
| pubmed-article:16343292 | pubmed:meshHeading | pubmed-meshheading:16343292... | lld:pubmed |
| pubmed-article:16343292 | pubmed:meshHeading | pubmed-meshheading:16343292... | lld:pubmed |
| pubmed-article:16343292 | pubmed:meshHeading | pubmed-meshheading:16343292... | lld:pubmed |
| pubmed-article:16343292 | pubmed:meshHeading | pubmed-meshheading:16343292... | lld:pubmed |
| pubmed-article:16343292 | pubmed:meshHeading | pubmed-meshheading:16343292... | lld:pubmed |
| pubmed-article:16343292 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:16343292 | pubmed:articleTitle | Effect of tepoxalin on renal function in healthy dogs receiving an angiotensin-converting enzyme inhibitor. | lld:pubmed |
| pubmed-article:16343292 | pubmed:affiliation | Unité de Physiopathologie Animale et Pharmacologie Fonctionnelle, UPSP, ENV Nantes, Nantes Cedex, France. | lld:pubmed |
| pubmed-article:16343292 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16343292 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
